Inspiration, imagination, and innovation. We share this passion for finding new approaches to protecting vision. United by great science, deep clinical insight, and a singular focus on your ophthalmic needs, we see the possibilities ahead and invite you to join us in creating the future of eye care.
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialisation of first-in-class therapies for the treatment of glaucoma and other diseases of the eye.
See the future of eye care with Aerie.
Aerie currently employs 120 located in the US and EU with plans to expand to 160 in 2017 and beyond in 2018. Headquartered in Irvine – CA we are also located in Bedminster - NJ, Raleigh/Durham - NC, Dublin & Malta. We are building our broader organisation in readiness for the commercialisation of our products, and the supply of same via our first manufacturing facility located in Athlone, Ireland.
Aerie have acquired the 2,650m2 IDA Advanced Technology Building in Athlone and will embark on an initial investment of $60m. A fast track start-up, our new sterile filling plant will be designed, constructed and validated for the global supply of our ophthalmic products with a target first regulatory approval & commercialization in early 2020. The plant will include end to end operations – compounding, sterile filling, and packaging with all support capabilities (QC labs, warehousing, etc.).